Drug Profile
CX 417
Alternative Names: CX417Latest Information Update: 06 Mar 2008
Price :
$50
*
At a glance
- Originator Cortex Pharmaceuticals
- Class Antidementias; Neuroprotectants
- Mechanism of Action Neurotransmitter receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 06 Mar 2008 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 29 Jun 2001 No Development Reported for Alzheimer's disease in USA (unspecified route)
- 04 Nov 1996 Suspended - Preclinical for Alzheimer's disease in USA (unspecified route)